401 related articles for article (PubMed ID: 30133790)
1. What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICI-RS 2017.
Malde S; Fry C; Schurch B; Marcelissen T; Averbeck M; Digesu A; Sahai A
Neurourol Urodyn; 2018 Jun; 37(S4):S108-S116. PubMed ID: 30133790
[TBL] [Abstract][Full Text] [Related]
2. How can we better manage drug-resistant OAB/DO? ICI-RS 2018.
Chermansky C; Schurch B; Rahnama'i MS; Averbeck MA; Malde S; Mancini V; Valentini F; Sahai A
Neurourol Urodyn; 2019 Dec; 38 Suppl 5():S46-S55. PubMed ID: 31821628
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review.
Rachaneni S; Latthe P
Int Urogynecol J; 2017 Jun; 28(6):805-816. PubMed ID: 28083714
[TBL] [Abstract][Full Text] [Related]
4. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
5. Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex.
Su X; Nickles A; Nelson DE
BMC Urol; 2015 Jun; 15():50. PubMed ID: 26055982
[TBL] [Abstract][Full Text] [Related]
6. [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A].
Amend B; Castro-Diaz D; Chartier-Kastler E; De Ridder D; Everaert K; Spinelli M; van Kereebroeck P; Sievert KD
Urologe A; 2010 Feb; 49(2):245-52. PubMed ID: 19859688
[TBL] [Abstract][Full Text] [Related]
7. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
[TBL] [Abstract][Full Text] [Related]
8. Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014.
Apostolidis A; Rahnama'i MS; Fry C; Dmochowski R; Sahai A
Neurourol Urodyn; 2016 Feb; 35(2):293-8. PubMed ID: 26872570
[TBL] [Abstract][Full Text] [Related]
9. [INJECTION OF BOTULINUM TOXIN TYPE A IN THE BLADDER DETRUSOR AND SUBMUCOSA IN PATIENTS WITH OVERACTIVE BLADDER WITHOUT DETRUSOR OVERACTIVITY].
Krivoborodov GG; Tur EI; Efremov NS
Urologiia; 2015; (2):31-4. PubMed ID: 26237802
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
Conte A; Giannantoni A; Proietti S; Giovannozzi S; Fabbrini G; Rossi A; Porena M; Berardelli A
Eur J Neurol; 2012 May; 19(5):725-32. PubMed ID: 22212295
[TBL] [Abstract][Full Text] [Related]
11. Intradetrusor injection of botulinum toxin A and sacral neuromodulation for neurogenic detrusor overactivity.
Joussain C; Phé V; Even A; Chartier-Kastler E; Denys P
Eur J Phys Rehabil Med; 2017 Dec; 53(6):991-997. PubMed ID: 29072045
[TBL] [Abstract][Full Text] [Related]
12. Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity.
Kanagarajah P; Ayyathurai R; Caruso DJ; Gomez C; Gousse AE
Int Urol Nephrol; 2012 Feb; 44(1):91-7. PubMed ID: 21643644
[TBL] [Abstract][Full Text] [Related]
13. A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.
Álvares RA; Araújo ID; Sanches MD
BMC Urol; 2014 Aug; 14():66. PubMed ID: 25123234
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin A for refractory OAB and idiopathic urinary retention: Can phenotyping improve outcome for patients: ICI-RS 2019?
Malde S; Apostilidis A; Selai C; Rahnama'i MS; Marcelissen T; Cardozo L; Lovick T
Neurourol Urodyn; 2020 Jul; 39 Suppl 3():S104-S112. PubMed ID: 31692092
[TBL] [Abstract][Full Text] [Related]
15. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
Mangera A; Apostolidis A; Andersson KE; Dasgupta P; Giannantoni A; Roehrborn C; Novara G; Chapple C
Eur Urol; 2014 May; 65(5):981-90. PubMed ID: 24239446
[TBL] [Abstract][Full Text] [Related]
16. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
Nambiar A; Lucas M
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
[TBL] [Abstract][Full Text] [Related]
17. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
Sahai A; Sangster P; Kalsi V; Khan MS; Fowler CJ; Dasgupta P
BJU Int; 2009 Mar; 103(5):630-4. PubMed ID: 18990156
[TBL] [Abstract][Full Text] [Related]
18. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
Tubaro A; Puccini F; De Nunzio C
Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
[TBL] [Abstract][Full Text] [Related]
19. Factors that influence the urodynamic results of botulinum toxin in the treatment of neurogenic hyperactivity.
Gutiérrez-Martín P; Vírseda-Chamorro M; Salinas Casado J; Gómez-Rodríguez A; Esteban-Fuertes M
Actas Urol Esp; 2015 May; 39(4):217-21. PubMed ID: 25582926
[TBL] [Abstract][Full Text] [Related]
20. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
